2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: Optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia

Authors


  • The Cytometry Part B: Clinical Cytometry supplement (72B, Supplement 1, 2007) titled ‘2006 Bethesda International Consensus Conference on Flow Cytometric Immunophenotyping of Hematolymphoid Neoplasia’ is sponsored by the Clinical Cytometry Society and the Clinical Cytometry Foundation. The Conference was supported by AmeriPath, ARUP, Beckman Coulter, BD Biosciences, CLARIENT, Clinical Cytometry Foundation, Clinical Cytometry Society, GENOPTIX, Genzyme, Laboratory Corporation of America, Trillium Diagnostics, National Cancer Institute, and Wallace H. Coulter Foundation. The contributing authors to this article have declared the following conflicts of interest: Brent Lee Wood has acted as a paid consultant and/or accepted speaker's fees from BD Biosciences and Beckman Coulter in the past, but has received no funding relevant to the current work. Teri Oldaker is employed by and holds stock in Genzyme Corporation, who is a sponsor for the event. The remaining authors have declared no conflicts of interest.

Abstract

Immunophenotyping by flow cytometry has become standard practice in the evaluation and monitoring of patients with hematopoietic neoplasia. However, despite its widespread use, considerable variability continues to exist in the reagents used for evaluation and the format in which results are reported. As part of the 2006 Bethesda Consensus conference, a committee was formed to attempt to define a consensus set of reagents suitable for general use in the diagnosis and monitoring of hematopoietic neoplasms. The committee included laboratory professionals from private, public, and university hospitals as well as large reference laboratories that routinely operate clinical flow cytometry laboratories with an emphasis on lymphoma and leukemia immunophenotyping. A survey of participants successfully identified the cell lineage(s) to be evaluated for each of a variety of specific medical indications and defined a set of consensus reagents suitable for the initial evaluation of each cell lineage. Elements to be included in the reporting of clinical flow cytometric results for leukemia and lymphoma evaluation were also refined and are comprehensively listed. The 2006 Bethesda Consensus conference represents the first successful attempt to define a set of consensus reagents suitable for the initial evaluation of hematopoietic neoplasia. © 2007 Clinical Cytometry Society

Ancillary